Ad
related to: pharmaceutical fraud lawsuits examples
Search results
Results From The WOW.Com Content Network
Legal claims against the pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud, off-label promotion, and inadequate manufacturing practices. [ 3 ] [ 4 ] With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act ...
For example, Purdue Pharmaceuticals entered an agreement with the United States, pleading guilty to felony misbranding of OxyContin with intent to defraud and mislead under sections 33 1(a) and 333(a)(2) of the FD&C Act and agreed to pay more than $600 million, but only $160 million was allocated to resolve civil claims under the False Claims ...
On December 9, 2016, pharmaceutical company Bristol-Myers Squibb agreed to pay $19.5 million to settle claims with forty-three state attorneys general concerning the alleged off-label promotion of its schizophrenia drug Abilify. [50] The lawsuit alleged the company promoted the drug for use in pediatric populations and to treat dementia and ...
CVS and Walgreens. $10.7 billion. CVS and Walgreens have agreed to settle lawsuits brought against the companies by several states for their alleged role in the opioid crisis. CVS would pay nearly ...
Members of the family who own OxyContin maker Purdue Pharma, and the company itself, agreed to pay up to $7.4 billion in a new settlement to lawsuits over the toll of the powerful prescription ...
Novo Nordisk Inc. settled two lawsuits on Friday, agreeing to pay more than $25 million to settle lawsuits that accused the pharmaceutical manufacturer of illegally promoting a bleeding disorder ...
Pharmaceutical fraud is when pharmaceutical companies engage in illegal, fraudulent activities to the detriment of patients and/or insurers. Examples include counterfeit drugs that do not contain the active ingredient, false claims in packaging and marketing, suppression of negative information regarding the efficacy or safety of the drug, and violating pricing regulations.
The drug is currently in a late-stage clinical trial, and some 735 patients had participated as of May 2024, according to a news release from Cassava last month. Wang did not immediately respond ...